Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Food Effect Study of TAK-385 Final Formulation
Phase 1
Completed
- Conditions
- Japanese Premenopausal Healthy Adult Women
- Interventions
- Drug: TAK-385 40 mg
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02792062
A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02791438
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Phase 4
Completed
- Conditions
- Pouchitis
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 102
- Registration Number
- NCT02790138
- Locations
- 🇧🇪
UZ Leuven - University Hospital Gasthuisberg, Leuven, Belgium
🇳🇱Academic Medical Center, Amsterdam, Netherlands
🇮🇹Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
Completed
- Conditions
- Lymphoma, T-Cell, Peripheral
- Interventions
- Other: No Intervention
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 198
- Registration Number
- NCT02788916
TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 16
- Registration Number
- NCT02774902
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02771093
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
Phase 1
Terminated
- Conditions
- Alzheimer DiseaseHealthy Volunteers
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 179
- Registration Number
- NCT02769065
Triple Combination Therapy in High Risk Crohn's Disease (CD)
Phase 4
Completed
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 55
- Registration Number
- NCT02764762
- Locations
- 🇺🇸
Cotton O'Neil Clinical Research, Topeka, Kansas, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇨🇦PerCuro Clinical Research Ltd, Victoria, British Columbia, Canada
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- Other: No Intervention
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 4253
- Registration Number
- NCT02761187
- Locations
- 🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Poudre Valley Health System, Fort Collins, Colorado, United States
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
Phase 4
Withdrawn
- Conditions
- Colitis, UlcerativeCrohn Disease
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Takeda
- Registration Number
- NCT02760615
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
🇺🇸QPS MRA, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath